Source:http://linkedlifedata.com/resource/pubmed/id/12827614
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2003-6-26
|
| pubmed:abstractText |
Thyroid transcription factor 1 (TTF-1), a homeodomain-containing transcription factor, plays a pivotal role in lung development, cell growth, and differentiation processes. The current literature reports considerable variation in frequency of TTF-1 protein expression in human non-small cell lung cancer (NSCLC). TTF-1 expression has not been extensively investigated as a prognostic marker in NSCLC. To assess the prevalence of TTF-1 expression, and to evaluate its potential role in disease prognosis, 140 stage I-IIIA NSCLCs with long-term follow-up were studied under uniform conditions using high-density tissue microarray (TMA) combined with immunohistochemistry. Patient survival and association of TTF-1 expression with clinicopathologic parameters were analyzed. One hundred twenty-six tumor samples were fully assessable after tissue processing. Sixty-four samples (50.8%) expressed TTF-1 and 62 (49.2%) displayed no expression. TTF-1 expression was significantly (P < 0.001) correlated with histological subtype: 51 adenocarcinomas (AdCs) (51 of 75; 68%) versus 9 squamous cell carcinomas (SCCs) (9 of 43; 21%) were TTF-1 positive. TTF-1 expression, performance status, nodal status, and tumor stage were significantly related to patient survival. In multivariate analysis, positive TTF-1 expression tended to favor a better patient outcome (P = 0.05). Overall, NSCLC patients with positive TTF-1 expression had a median survival of greater than 57.3 months, whereas those with negative expression had a median survival of 39.4 +/- 5.2 months (log-rank test, P = 0.0067). In this study we found that TTF-1 is predominately expressed in adenocarcinoma. The loss of TTF-1 expression was associated with aggressive behavior of NSCLCs. The results from this study strongly indicate that further investigation is warranted to better define the role of TTF-1 as a prognostic factor in this malignancy.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0046-8177
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
34
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
597-604
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:12827614-Adenocarcinoma,
pubmed-meshheading:12827614-Adult,
pubmed-meshheading:12827614-Aged,
pubmed-meshheading:12827614-Aged, 80 and over,
pubmed-meshheading:12827614-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:12827614-Carcinoma, Squamous Cell,
pubmed-meshheading:12827614-Female,
pubmed-meshheading:12827614-Histocytological Preparation Techniques,
pubmed-meshheading:12827614-Humans,
pubmed-meshheading:12827614-Immunohistochemistry,
pubmed-meshheading:12827614-Lung Neoplasms,
pubmed-meshheading:12827614-Male,
pubmed-meshheading:12827614-Middle Aged,
pubmed-meshheading:12827614-Neoplasm Staging,
pubmed-meshheading:12827614-Nuclear Proteins,
pubmed-meshheading:12827614-Survival Rate,
pubmed-meshheading:12827614-Transcription Factors,
pubmed-meshheading:12827614-Tumor Markers, Biological
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study.
|
| pubmed:affiliation |
Lung Cancer Program, Roswell Park Cancer Institute, State University of New York, Buffalo, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|